We assessed vitamin D status in HIV-infected patients and its relation to classic, related-HIV risk factors and therapeutic regimens.
Results
Median CD4' cell count was 501 cells/mL; median VL 40 copies/mL. 277 patients (78.7%) had less than 50 copies/mL. 310 patients (88.1%) were on cART. The proportions of patients with vitDd, vitDi and vitDo were 155/352 (44%), 97 (27.6%) and 100 (28.5%). Black patients had 14.2% of vitDd (22 patients out of 155 patients with vitDd), 7.2% (7/97) vitDi and 1% (1/100) vitDo (p 0.001) vs. global sample; therefore, 29 out of 30 (96.7%) black patients had vitDd/vitDi, vs. 71.6% in global sample. Former IDUs had more vidDo (p B0.001 vs. other risk groups). Among patients with less than 50 copies/mL, the proportions of vitDd, vitDi and vitDo were 77.4%, 68% and 91% respectively, (p 0.0001). Of the cART, only PI monotherapy was associated with significant differences in vitD (see Table) . 
